Complan and the "Growth" Promise: An MBA Case Study in Sustaining a Legacy Nutrition Brand Under Ownership Change and Regulatory Pressure

Industry & Competitive Context

Complan competes in India's health food drinks (HFD) category malt- and milk-based nutrition powders consumed by mixing with milk, historically marketed on child growth and family nutrition. Industry estimates place the category at roughly $1 billion in India, with Horlicks the clear leader at approximately 44–47% market share, Bournvita holding a "double-digit" share, and Boost and Complan each estimated at around 5% of the category, according to Business Standard's reporting on the sector in 2024. Zydus Wellness's own FY2023-24 Annual Report states that the category grew 6.4% on a Moving Annual Total (MAT) basis to March 2024, and that Complan's market share stood at 4.3% as per the MAT March 2024 report referenced in that filing. The company's most recent disclosure (FY2025-26 results, reported May 2026) states Complan "maintained its fourth rank, holding a 4% market share" in the category.

This is a mature, slow-growing, and consolidated category. A widely cited industry teaching document (a communications-strategy case on Horlicks) similarly describes the HFD category as having seen "declining growth in recent years" with category leader Horlicks itself slowing to single-digit growth, attributing this to rising nutritional security from other food sources, a consumer shift toward "natural" and organic positioning, and children's own brand preferences increasingly shaping household purchase decisions. Complan operates as a smaller, sub-scale player in a category dominated by Horlicks, a brand owned by Hindustan Unilever (HUL), alongside HUL's own Boost and Mondelez's Bournvita.

A significant, publicly documented, category-wide disruption occurred in 2024: following a year-long inquiry by the National Commission for the Protection of Child Rights (NCPCR) into Bournvita's sugar content triggered by a viral social media critique from consumer-advocacy creator Revant Himatsingka ("Food Pharmer") India's Ministry of Commerce and Industry directed e-commerce platforms in April 2024 to stop listing malt-, cereal-, and dairy-based drinks under the "health drinks" category, per Business Standard and the Food Safety and Standards Authority of India's (FSSAI) own advisory cited in that reporting. Platforms including Amazon and Flipkart subsequently reclassified Horlicks, Bournvita, Boost, and comparable products under labels such as "food drink" or "nutrition drink." This is documented industry context that affected the category Complan competes in, though no public source in this research confirms a brand-specific Complan directive distinct from the sector-wide change.

Brand Situation Prior to Campaign

Complan was launched by the British pharmaceutical company Glaxo; the brand's global launch dates to 1954, according to MBA Skool's marketing-mix profile, while a separately sourced marketing report places its India market entry in 1964. Its earliest positioning, as documented in multiple retrospectives including the Marketing Monk brand history and MBA Skool, was clinical rather than aspirational: Complan built its early reputation as a supplement for convalescents and hospital patients, a legacy of its ownership by a pharmaceutical company rather than a consumer-foods company. Ownership passed from Glaxo to the British retailer Boots in 1988 (UK operations), and then to Heinz, which acquired the company including both UK and India operations in 1994, according to MBA Skool's account of the brand's ownership history.

Under Heinz, Complan repositioned toward a "lifestyle" nutrition brand and began directly targeting the children's-growth segment, according to a feature published by ThePrint in 2021. It was under Heinz that the brand adopted the claim that Complan supported "two times faster growth" in children a claim explicitly documented and subsequently disputed by regulators, discussed below.

Kraft Heinz sold its India business including full global intellectual property rights to Complan, Glucon-D, Nycil, and Sampriti to Zydus Wellness Limited and its promoter Cadila Healthcare Limited. Per Kraft Heinz's own SEC filings (Form 10-Q, Q1 FY2019), the transaction was agreed in October 2018 for approximately ₹46 billion (approximately $655 million at the January 30, 2019 closing date), and Kraft Heinz recognized a pre-tax gain of $246 million on the sale. Bloomberg's contemporaneous reporting cited the deal value as $628 million, and Business Standard reported the rupee figure as ₹4,595 crore. Business Standard also reported that combined revenues from Complan, Glucon-D, Nycil, and Sampriti Ghee were approximately ₹1,150 crore for the twelve months ended June 30 (of the reported period), and that the acquisition would take Zydus Wellness's annual revenue to approximately ₹1,700 crore. The deal closed on January 30, 2019.

Strategic Objective

Based on public statements from Zydus Wellness leadership and its own investor disclosures, the company's stated strategic priorities for Complan following the 2019 acquisition centre on two objectives that recur across its annual reports and press releases: (1) defending and modestly growing market share in a mature, declining-growth category against a dominant leader (Horlicks) and comparably sized rivals (Bournvita, Boost); and (2) renewing the brand's relevance with a new generation of parents whose nutritional concerns have broadened beyond height alone. Zydus Wellness CEO Tarun Arora's statement accompanying the 2024 relaunch campaign "Complan is an iconic brand in children's health food drink category and contains 100% milk protein" frames the brand's positioning objective explicitly around protein-led nutrition credentials rather than height alone, as reported by Mediabrief and Afaqs.

Campaign Architecture & Execution

Complan's advertising has evolved through several publicly documented phases:

The "growth = height" era. According to the Marketing Monk brand history, market research conducted by Manunath Hegde among mothers the primary purchase decision-makers found that for this audience, a child's "growth" was understood principally as height. This insight underpinned decades of advertising built around the "I'm a Complan Boy / I'm a Complan Girl" tagline, which multiple sources (Marketing Monk, MBA Skool, Afaqs) describe as the brand's most recognised and enduring campaign asset. Early television and print advertising for the brand also featured child actors who later became well-known film performers, including Shahid Kapoor and Ayesha Takia, per the Marketing Monk account. The brand also historically positioned itself directly against milk, using the comparative claim "Milk has only 9 vital ingredients, Complan has 23," as documented in a marketing case analysis (PGP Media & Entertainment) and echoed in MBA Skool's marketing-mix summary.

Language and audience broadening. Marketing Monk's brand history notes that Complan's earlier advertising ran predominantly in English, supporting a premium positioning, before the brand shifted toward Hindi-language advertising to reach a wider consumer base, and toward regional-celebrity endorsement to reach South Indian markets specifically.

Celebrity-led relaunch (2024). In January 2024, under Zydus Wellness ownership, Complan launched a new campaign featuring Madhuri Dixit, positioned as the face of the campaign in Hindi-speaking markets, and Sneha, positioned for southern Indian markets a continuation of the brand's earlier regional-celebrity segmentation strategy. The television commercial was conceptualised by McCann Worldgroup India and released in five languages Hindi, Marathi, Bengali, Tamil, and Telugu across television, digital, and social media platforms, per Afaqs' and Mediabrief's coverage. The creative depicted the two actors, in their capacity as mothers, discussing children's protein needs with other parents at a school event, building toward the claim that Complan contains "63% more protein" than a comparator kids' health-food drink and "34 vital nutrients," delivering "2X faster growth" and supporting "memory and concentration" with the commercial closing on the legacy "I'm Complan Boy/Girl" tagline, per Mediabrief's reporting.

Category-repositioning campaign (2026). Per Open Magazine's reporting, Complan more recently launched a campaign titled "Thoda Plan, Thoda Complan," featuring an association with teenage cricketer Vaibhav Sooryavanshi, described in the coverage as positioning the athlete as "a symbol of discipline, routine and preparation." Open Magazine's analysis characterises this as a deliberate narrative shift away from the brand's historical singular emphasis on height gain, toward broader claims around stamina, focus, and "all-round development" reflecting, in the publication's framing, a category-wide evolution in what parents seek from children's nutrition products beyond height.

Product-level adaptation. Zydus Wellness's FY2023-24 Annual Report documents that Complan was made available in a 700-gram pouch format, described as a response to rising consumer preference for smaller pack sizes in the HFD category. The company's FY2025-26 results additionally note the commercial rollout of a variant named Complan NutriGro within the kids' nutrition segment, with "direct supply" of this variant beginning during that quarter.

Positioning & Consumer Insight

The consistent, sourced insight underlying Complan's advertising is that Indian mothers historically the brand's identified primary purchasers associate a child's "growth" most immediately with physical height, a finding attributed to market research by Manunath Hegde and cited in Marketing Monk's brand history. This insight shaped the brand's core promise for decades and is directly reflected in its most recognised tagline. More recent public communications the 2024 campaign's emphasis on protein content and cognitive support, and the 2026 campaign's emphasis on stamina and discipline via a cricket association indicate a documented shift in the stated consumer proposition, from a singular height-based promise toward a broader, multi-attribute nutrition narrative (protein, memory, concentration, stamina, preparation). Open Magazine's reporting explicitly frames this shift as a response to changing parental priorities, citing "stamina, focus, immunity and overall development" as themes that have supplanted a narrower height-centred pitch.

Media & Channel Strategy

Verified, sourced channel information is limited to specific, named campaign instances rather than a comprehensive media plan. Marketing Monk's brand history states that Complan's early advertising ran across radio, newspapers, and print, and explicitly notes that the brand did not use cinema advertising because other channels were considered more measurable at the time though no source specifies the period this refers to precisely, nor any measurement methodology. For the 2024 Madhuri Dixit/Sneha campaign, Afaqs reported that the television commercial, produced by McCann Worldgroup India, was released across television (in five languages) as well as the brand's digital and social media platforms. MBA Skool's marketing-mix analysis also notes that the brand has used sports sponsorship, citing its sponsorship of the Junior Squash Open in 2002, and has more broadly relied on celebrity endorsement across both film and sport, consistent with the 2026 cricket-led "Thoda Plan, Thoda Complan" campaign.

Business & Brand Outcomes

Publicly disclosed, company-sourced outcome data for Complan specifically is limited and is presented here without extrapolation:

• Zydus Wellness's FY2023-24 Annual Report states total company revenue from operations of ₹23,278 million (+3.2% year-on-year), and separately notes that the company's food and nutrition segment (which includes Complan) reported "flattish growth" for that year, against category (HFD) growth of 6.4% on an MAT basis.

  
  

• Complan's market share was reported at 4.3% (MAT March 2024) in the FY2023-24 Annual Report, and at approximately 4% (fourth rank in category) in the company's FY2025-26 results announcement (May 2026).

  
  

• Independent equity-research commentary (a third-party SWOT analysis, not a company disclosure) describes Complan's market share within the nutrition-drinks category as "stagnant," and states that "Legacy brand Complan has maintained a modest market share," framing it as a limiting factor on the company's broader growth in that segment. This is analyst commentary, not a company-verified figure, and is presented as such.

  
  

• The company's FY2025-26 consolidated net sales grew 46.4% year-on-year to ₹39,400 million; however, the company's own reporting and third-party coverage attribute the large majority of this growth to the acquisition of UK-based Comfort Click Limited (announced at an equity value of £242 million) rather than to organic performance of legacy brands such as Complan.

  
  

• Regulatory history: the Advertising Standards Council of India (ASCI) sent a notice to Heinz India in 2007 requesting that the company change or remove advertising claiming Complan could increase a child's height "by as much as two times," according to ThePrint's reporting; the same report states that no change to the advertising resulted. In May 2010, the Maharashtra Food and Drug Administration filed a chargesheet against Complan over what it described as an "exaggerated" advertising claim that the product helps children "grow twice as fast," per ThePrint. ThePrint's reporting further documents that, four months after the chargesheet, an 11-year-old boy in Delhi died by suicide, a case that received press coverage at the time in connection with unmet expectations from the product's height-related marketing claims; ThePrint reports that the company's marketing strategy did not change following this event. This is a sensitive matter and is reported here strictly as documented by the cited news source, without further characterisation or speculation about causation.

Strategic Implications

Three points emerge directly from the verified record and merit analytical attention, rather than speculative extension:

First, Complan's history illustrates how ownership transitions reshape brand positioning even when core assets (the name, the tagline, the "growth" promise) persist. The shift from a pharmaceutical parent (Glaxo) to a foods conglomerate (Heinz) to a domestic wellness company (Zydus Wellness) corresponds, in the documented record, to a shift from clinical framing, to aggressive lifestyle and growth-claim marketing, to a more diversified, protein- and stamina-oriented narrative under current ownership a trajectory consistent with each owner's broader portfolio logic.

Second, the brand operates in a category facing simultaneous regulatory and reputational headwinds that are documented at the industry level (the FSSAI/Commerce Ministry "health drink" reclassification of 2024) as well as at the brand level (the 2007 ASCI notice and 2010 Maharashtra FDA chargesheet specifically concerning Complan's growth claims). The persistence of "growth"-oriented and comparative claims across multiple owners, despite two distinct regulatory challenges over more than a decade, suggests the claim has been treated by successive owners as a durable commercial asset even amid scrutiny a tension the public record does not resolve in terms of long-run brand-equity cost or benefit.

Third, recent campaign architecture (2024's protein-led relaunch; 2026's stamina- and discipline-led cricket association) indicates a documented but incremental repositioning away from a single-attribute claim (height) toward a multi-attribute nutrition narrative, occurring in parallel with a category-wide contraction in the credibility of blanket "health drink" positioning. Whether this repositioning has altered the brand's competitive position is not something the public record limited to a stated 4% category share as of FY2025-26 currently allows one to determine with confidence, and no verified public information is available on a causal link between any specific campaign and subsequent market-share movement.

Discussion Questions

1. Complan's ownership passed from a pharmaceutical company (Glaxo) to a food conglomerate (Heinz) to a domestic wellness company (Zydus Wellness). Using only the documented positioning shifts at each stage, assess how a parent company's core business model appears to shape the brand identity it assigns to an acquired asset.

   
   

2. The brand's core insight that mothers equate "growth" with "height" sustained a market-leading tagline for decades but also attracted two documented regulatory challenges (ASCI in 2007, Maharashtra FDA in 2010). How should a marketing team weigh the commercial durability of a consumer insight against escalating regulatory and reputational risk when the insight itself is the basis of the contested claim?

   
   

3. Complan holds an estimated 4% category share against Horlicks' approximately 44–47%, in a category whose growth Zydus Wellness's own filings describe as "flattish" for the food and nutrition segment. What strategic options are available to a distant-second-tier brand in a mature, regulator-constrained category where the dominant player's own growth has also slowed?

   
   

4. The 2024 industry-wide reclassification of "health drinks" (triggered by scrutiny of a competitor, Bournvita, rather than of Complan itself) affected the entire category's marketing language. Discuss how brands should prepare for regulatory or reputational shocks that originate with a competitor but affect an entire product category's claims architecture.

   
   

5. Complan's advertising has moved from a single-attribute promise (height) to a multi-attribute narrative (protein, memory, stamina, discipline) across its 2024 and 2026 campaigns. Based only on the publicly disclosed share and revenue data available (not assumed outcomes), what evidence would be required to determine whether this repositioning is succeeding, and what specific disclosures would a case researcher need from the company to answer that question rigorously?